Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ITGA5 Predicts Dual-Drug Resistance to Temozolomide and Bevacizumab in Glioma

17 Dec 2021

Abstract excerpt

Aims Anti-angiotherapy (Bevacizumab) is currently regarded as a promising option for glioma patients who are resistant to temozolomide (TMZ) treatment. But ongoing clinical research failed to meet therapeutic expectations. This study aimed to explore the pivotal genetic feature responsible for TMZ and Bevacizumab resistance in glioma patients. Methods We downloaded the transcriptomic and methylation data of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis and VEGF in Cancer
Share to Caveolin-1 and cellular processes
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34976814
DOI: 10.3389/fonc.2021.769592

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ITGA5 Predicts Dual-Drug Resistance to Temozolomide and Bevacizumab in GliomaPMID 34976814Read ↗

ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in GliomasSemantic proximity Read ↗

Functional genomics identifies therapeutic options, biomarkers, and resistance mechanisms for high-grade gliomasSemantic proximity Read ↗

ITGA5 induces mesenchymal transformation to promote gliomas progression via PI3K/AKT/mTORC1 signaling pathwaySemantic proximity Read ↗

Identifying Predictive Gene Expression and Signature Related to Temozolomide Sensitivity of GlioblastomasSemantic proximity Read ↗

Identification of novel drug resistance mechanisms by genomic and transcriptomic profiling of glioblastoma cells with mutation-activated EGFR.Semantic proximity Read ↗

Prostaglandin F2 receptor inhibitor (PTGFRN) a cell adhesion molecule, promotes cell growth and migration in glioblastomaSemantic proximity Read ↗

Analysis and Construction of ceRNA Networks Reveal 4 mRNAs as Potential Biomarkers of Temozolomide-resistant GlioblastomasSemantic proximity Read ↗

Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.Semantic proximity Read ↗

Identification of inter- and intra-tumoral molecular phenotypes steering temozolomide resistance in patient-derived glioblastoma cellsSemantic proximity Read ↗

MicroRNAs as the pivotal regulators of Temozolomide resistance in glioblastomaSemantic proximity Read ↗

Drug metabolism-related gene ABCA1 augments temozolomide chemoresistance and immune infiltration abundance of M2 macrophages in gliomaSemantic proximity Read ↗

ATM Knockdown renders Glioma resistant to Temozolomide by Inhibiting IFIT1 ExpressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.